Immunomodulatory effects of intravenous immunoglobulins;Effets immunomodulateurs des immunoglobulines intraveineuses

Presse Medicale

Volumn 33, Issue 17, 2004, Pages 1183-1194

  Guilpain, Philippe ^a   Chanseaud, Youri ^b   Tamby, Mathieu C ^b   Larroche, Claire ^c   Guillevin, Loïc ^a   Kaveri, Srini V ^d   Kazatchkine, Michel D ^d   Mouthon, Luc ^a,b  

^a Université Paris V ^*  (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c AVICENNE HOSPITAL   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CELL ADHESION MOLECULE; COMPLEMENT; CORTICOSTEROID; ENDOBULINE; FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; NEUTRALIZING ANTIBODY; SANDOGLOBULINE;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL SURFACE; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; IMMUNOMODULATION; INFLAMMATION; LEUKOCYTE; LYMPHOCYTE; MONOCYTE; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 5644230959     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(04)98888-4     Document Type: Short Survey

References (171)

1. Mouthon L, Lortholary O. Intravenous Immunoglobulins (IVIg) therapy in infectious diseases: where do we stand? (editorial). Clin microbiol Infect 2003; 9: 333-8.
2. Imbach P, Barandun S, D'apuzzo V et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1(8232): 1228-31.
3. Van Der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 1992; 326: 1123-9.
4. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet 1997; 349: 225-30.
5. Vermeulen M, Van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993; 56: 36-9.
6. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, crossover study. Brain 1996; 119 (Pt 4): 1067-77.
7. Thompson N, Choudhary P, Hughes RA, Quinlivan RM. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1996; 243: 280-5.
8. Mendell JR, Barohn RJ, Freimer ML et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001; 56: 445-9.
9. Léger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001; 124(Pt 1): 145-53.
10. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 1997; 41: 789-96.
11. Dalakas MC, Illa I, Dambrosia JM et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993-2000.
12. Cherin P, Pelletier S, Teixeira A et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002; 46: 467-74.
13. Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, Mcelroy B. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 2001; 345: 1870-6.
14. Newburger JW, Takahashi M, Burns JC et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315: 341-7.
15. Le Hoang P, Cassoux N, Georges F, Kullman N, Kazatchkine MD. Intravenous Immunoglobulins (IVIg) for the treatment of Birdshot retinopathy. Ocul Immunol Inflamm 2000; 8: 49-57.
16. Bjorkholm M. Intravenous immunoglobulin treatment in cytopenic haematological disorders. J Intern Med 1993; 234: 119-26.
17. Hilgartner Mw, Bussel J. Use of intravenous gamma globulin for the treatment of autoimmune neutropenia of childhood and autoimmune hemolytic anemia. Am J Med 1987; 83: 25-9.
18. Macintyre EA, Linen DC, Macey MG, Newland AC. Successful response to intravenous immunoglobulin in autoimmune haemolytic anaemia. Br J Haematol 1985; 60: 387-8.
19. Jayne DR, Chapel H, Adu D et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000; 93: 433-9.
20. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-55.
21. Larroche C, Chanseaud Y, Garcia De La Pena-Lefebvre P, Mouthon L. Mechanisms of intravenous immunoglobulin action in the treatment of autoimmune disorders. BioDrugs 2002; 16: 47-55.
22. Pharmacopée européenne. Immunoglobulines humaines normales pour injection intraveineuse. 2002; monographie 0338.
23. Blasczyk R, Westhoff U, Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993; 341: 789-90.
24. Lam L, Whitsett CF, Mcnicholl JM, Hodge TW, Hooper J. Immunologically active proteins in intravenous immunoglobulin. Lancet 1993; 342: 678.
25. Kekow J, Reinhold D, Pap T, Ansorge S. Intravenous immunoglobulins and transforming growth factor beta. Lancet 1998; 351: 184-5.
26. Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 1982; 306: 1254-8.
27. Kimberly RP, Salmon JE, Bussel JB, Crow MK, Hilgartner MW. Modulation of mononuclear phagocyte function by intravenous gamma-globulin. J Immunol 1984: 132: 745-50.
28. Debré M, Bonnet MC, Fridman WH et al. Infusion of Fc γ fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 1993; 342: 945-9.
29. Clarkson SB, Bussel JB, Kimberly RP, Valinsky JE, Nachman RL, Unkeless JC. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc γ-receptor antibody. N Engl J Med 1986; 314: 1236-9.
30. Kurlander RJ. Reversible and irreversible loss of Fc receptor function of human monocytes as a consequence of interaction with immunoglobulin G. J Clin Invest 1980; 66: 773-81.
31. Kurlander RJ, Hall J. Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice. J Clin Invest 1986; 77: 2010-8.
32. Levy Y, Sherer Y, Ahmed A et al. Autoantibody level modification in adult patients with idiopathic thrombocytopenic purpura following intravenous immunoglobulin treatment. Nat Immun 1998; 16: 207-14.
33. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291: 484-6.
34. Scaradavou A, Woo B, Woloski BM et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997; 89: 2689-700.
35. Bruhns P, Samuelsson A, Pollard JW, Ravetch JV. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 2003; 18: 573-81.
36. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340: 227-8.
37. Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 1996; 93: 5512-16.
38. Leach JL, Sedmak DD, Osborne JM, Rahill B, Lairmore MD, Anderson CL. Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport. J Immunol 1996; 157: 3317-22.
39. Hansen RJ, Balthasar JP. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Stood 2002; 100: 2087-93.
40. Pierangeli SS, Espinola R, Liu X, Harris EN, Salmon JE. Identification of an Fc γ receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype. Arthritis Rheum 2001; 44: 876-83.
41. Bleeker WK, Teeling JL, Hack CE. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood 2001; 98: 3136-42.
42. Miletic VD, Hester CG, Frank MM. Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes. J Immunol 1996; 156: 749-57.
43. Basta M. Modulation of complement-mediated immune damage by intravenous immune globulin. Clin Exp Immunol 1996; 104 Suppl 1: 21-5.
44. Bing DH. Complement interaction with immune serum globulin and immune globulin intravenous. Am J Med 1984; 76(3A): 19-24.
45. Mollnes TE, Andreassen IH, Hogasen K, Hack CE, Harboe M. Effect of whole and fractionated intravenous immunoglobulin on complement in vitro. Mol Immunol 1997; 34: 719-29.
46. Rieben R, Roos A, Muizert Y, Tinguely C, Gerritsen AF, Daha MR. Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Blood 1999; 93: 942-51.
47. Basta M, Kirshbom P, Frank MM, Fries LF. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 1989; 84: 1974-81.
48. Dantas M, Costa RS, Barbosa JE, Graeff MS, Sarti W, De Carvalho IF. Intravenous immunoglobulin (IVIG) attenuates antibody binding in acute haemorrhagic immunopneumonitis in a rat model of complement-dependent lung injury. Clin Exp Immunol 2000; 121: 139-45.
49. Basta m, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invert 1994; 94: 1729-35.
50. Kamolvarin N, Hemachudha T, Ongpipattanakul B, Phanuphak P, Viddayakorn P, Sueblinvong T. Plasma C3c changes in myasthenia gravis patients receiving high-dose intravenous immunoglobulin during crisis. Acta Neurol Scand 1989; 80: 324-6.
51. Dalakas MC. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 1997; 126: 721-30.
52. Basta M, Fries LF, Frank MM. High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Stood 1991; 77: 376-80.
53. Basta M, Langlois PF, Marques M, Frank MM, Fries LF. High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood 1989; 74: 326-33.
54. Lutz Hu, Stammler P, Jelezarova E, Nater M, Spath PJ. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 1996; 88: 184-93.
55. Basta M, Van Goor F, Luccioli S et al. F(ab)(2)-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 2003; 9: 431-8.
56. Mollnes TE, Hogasen K, Hoaas BF, Michaelsen TE, Garred P, Harboe M. Inhibition of complement-mediated red cell lysis by immunoglobulins is dependent on the IG isotype and its C1 binding properties. Scand J Immunol 1995; 41: 449-56.
57. QI M, Schifferli JA. Inhibition of complement activation by intravenous immunoglobulins. Arthritis Rheum 1995; 38: 146.
58. Basta M, Fries LF, Frank MM. High doses of intravenous immunoglobulin do not affect the recognition phase of the classical complement pathway. Blood 1991; 78: 700-2.
59. Urbani L, Cardoso J, Soubrane O, Houssin D, Gautreau C. Fab fragments from intravenous immunoglobulin prevent hyperacute rejection in the guinea pig-to-rat combination without reducing hemolytic complement activity in rat serum. Transplant Proc 2000; 32: 2707-9.
60. Wassmuth R, Hauser IA, Schuler K et al. Differential inhibitory effects of intravenous immunoglobulin preparations on HLA-alloantibodies in vitro. Transplantation 2001; 71: 1436-42.
61. Dalakas MC. Clinical benefits and immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies. Clin Exp Immunol 1996; 104 Suppl 1: 55-60.
62. Okitsu-Negishi S, Furusawa S, Kawa Y et al. Suppressive effect of intravenous immunoglobulins on the activity of interleukin-1. Immunol Res 1994; 13: 49-55.
63. Shimozato T, Iwata M, Kawada H, Tamura N. Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3′:5′-monophosphate levels, resulting in suppression of tumour necrosis factor α and interleukin-1 production. Immunology 1991; 72: 497-501.
64. Suzuki H, Uemura S, Tone S et al. Effects of immunoglobulin and γ-interferon on the production of tumour necrosis factor-γ and interleukin-1 β by peripheral blood monocytes in the acute phase of Kawasaki disease. Eur J Pediatr 1996; 155: 291-6.
65. Sharief MK, Ingram DA, Swash M, Thompson EJ. I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barre syndrome. Neurology 1999; 52: 1833-8.
66. Ruiz de Souza V, Carreno MP, Kaveri SV et al. Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). Eur J Immunol 1995; 25: 1267-73.
67. Andersson J, Skansen-Saphir U, Sparrelid E, Andersson U. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 1996; 104 Suppl 1: 10-20.
68. Arend WP, Leung DY. IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol Rev 1994; 139: 71-8.
69. Arend WP, Smith MF, JR., Janson RW, Joslin FG. IL-1 receptor antagonist and IL-1 beta production in human monocytes are regulated differently. J Immunol 1991; 147: 1530-6.
70. Andersson U, Bjork L, Skansen-Saphir U, Andersson J. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994; 139: 21-42.
71. Aukrust P, Froland SS, Liabakk NB, et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994; 84: 2136-43.
72. Gullestad L, Aass H, Fjeld JG et al. Immunomodulating Therapy With Intravenous Immunoglobulin in Patients With Chronic Heart Failure. Circulation 2001; 103: 220-225.
73. Aukrust P, Muller F, Svenson M, Nordoy I, Bendtzen K, Froland SS. Administration of intravenous immunoglobulin (IVIG) in vivo-down-regulatory effects on the IL-1 system. Clin Exp Immunol 1999; 115: 136-43.
74. Bhol KC, Desai A, Kumari S, Colon JE, Ahmed AR. Pemphigus vulgaris: the role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production. Clin Immunol 2001; 100: 172-80.
75. Bruley Rosset M, Mouthon L, Chanseaud Y, Dhainaut F, Lirochon J, Bourel D. Polyreactive autoantibodies purified from human intravenous immunoglobulins prevent the development of experimental autoimmune diseases. Lab Invest 2003; 83: 1013-23
76. Toyoda M, Zhang X, Petrosian A, Galera OA, Wang SJ, Jordan SC. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. J Clin Immunol 1994; 14: 178-89.
77. Andersson UG, Bjork L, Skansen-Saphir U, Andersson JP. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 1993; 79: 211-6.
78. Menezes MC, Benard G, Sato MN, Hong MA, Duarte AJ. In vitro inhibitory activity of tumor necrosis factor α and interleukin-2 of human immunoglobulin preparations. Int Arch Allergy Immunol 1997; 114: 323-8.
79. Modiano JF, Amran D, Lack G, et al. Posttranscriptional regulation of T-cell IL-2 production by human pooled immunoglobin. Clin Immunol Immunopathol 1997; 83: 77-85.
80. Nachbaur D, Herold M, Eibl B et al. A comparative study of the in vitro immunomodulatory activity of human intact immunoglobulin (7S IVIG), F(ab′)2 fragments (5S IVIG) and Fc fragments. Evidence for post-transcriptional IL-2 modulation. Immunology 1997; 90: 212-18.
81. Skansen-Saphir U, Andersson J, Bjork L, Andersson U. Lymphokine production induced by streptococcal pyrogenic exotoxin-A is selectively down-regulated by pooled human IgG. Eur J Immunol 1994; 24: 916-22.
82. Takata Y, Seki S, Dobashi H et al. Inhibition of IL-12 synthesis of peripheral blood mononuclear cells (PBMC) stimulated with a bacterial superantigen by pooled human immunoglobulin: implications for its effect on Kawasaki disease (KD). Clin Exp Immunol 1998; 114: 311-19.
83. Toungouz M, Denys C, Dupont E. Blockade of proliferation and tumor necrosis factor-γ production occurring during mixed lymphocyte reaction by interferon-γ-specific natural antibodies contained in intravenous immunoglobulins. Transplantation 1996; 62: 1292-6.
84. Campbell DE, Georgiou GM, Kemp AS. Pooled human immunoglobulin inhibits IL-4 but not IFN-7gamma; TNF-α secretion following in vitro stimulation of mononuclear cells with Staphylococcal superantigen. Cytokine 1999; 11: 359-65.
85. Andersson JP, Andersson UG. Human intravenous immunoglobulin modulates monokine production in vitro. Immunology 1990; 71: 372-6.
86. Gupta M, Noel GJ, Schaefer M, Friedman D, Bussel J, Johann-Liang R. Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. J Clin Immunol 2001; 21: 193-9.
87. Ling ZD, Yeoh E, Webb ET, Farrell K, Doucette J, Matheson DS. Intravenous immunoglobulin induces interferon-γ and interleukin-6 in vivo. J Clin Immunol 1993; 13: 302-9.
88. Bagdasarian A, Tonetta S, Harel W, Mamidi R, Uemura Y. IVIG adverse reactions: potential role of cytokines and vasoactive substances. Vox Sang 1998; 74: 74-82.
89. Suzuki H, Noda E, Miyawaki M, Takeuchl T, Uemura S, Koike M. Serum levels of neutrophil activation cytokines in Kawasaki disease. Pediatr Int 2001; 43: 115-19.
90. Darville T, Tabor D, Simpson K, Jacobs RF. Intravenous immunoglobulin modulates human mononuclear phagocyte tumor necrosis factor-α production in vitro. Pediatr Res 1994; 35(4 Pt 1): 397-403.
91. Achiron A, Margalit R, Hershkoviz R et al. Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor α secretion. J Clin Invest 1994; 93: 600-5.
92. Zhuang Q, Bisotto S, Fixman ED, Mazer B. Suppression of IL-4- and CD40-induced B-lymphocyte activation by intravenous immunoglobulin is not mediated through the inhibitory IgG receptor FcγRIIb. J Allergy Clin Immunol 2002; 110: 480-3.
93. Damas JK, Gullestad L, Aass H et al. Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure-modulatory effect of intravenous immunoglobulin. J Am Coll Cardiol 2001; 38: 187-93.
94. Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 2001; 182: 207-14.
95. Keren G, Keren P, Barshack I, Pri-Chen S, George J. The effect of intravenous immunoglobulins on intimal thickening in a mouse model of arterial injury. Atherosclerosis 2001; 159: 77-83.
96. Blank M, Levy Y, Amital H, Shoenfeld Y, Pines M, Genina O. The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum 2002; 46: 1689-90.
97. Creange A, Belec L, Clair B, Degos JD, Raphael JC, Gherardi RK. Circulating transforming growth factor beta 1 (TGF-β1) in Guillain-Barre syndrome: decreased concentrations in the early course and increase with motor function. J Neurol Neurosurg Psychiatry 1998; 64: 162-5.
98. Krause I, Blank M, Sherer Y, Gilburd B, Kvapil F, Shoenfeld Y. Induction of oral tolerance in experimental antiphospholipid syndrome by feeding with polyclonal immunoglobulins. Eur J Immunol 2002; 32: 3414-24.
99. Bayry J, Lacroix-Desmazes S, Carbonneil C et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003; 101: 758-65.
100. Wadhwa M, Meager A, Dilger P et al. Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1α and interferon-α but not other cytokines in human immunoglobulin preparations. Immunology 2000; 99: 113-23.
101. Abe Y, Horiuchi A, Miyake M, Kimura S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994; 139: 5-19.
102. Bendtzen K, Hansen MB, Ross C, Poulsen LK, Svenson M. Cytokines and autoantibodies to cytokines. Stem Cells 1995; 13: 206-22.
103. Prasad NK, Papoff G, Zeuner A et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998; 161: 3781-90.
104. Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-3.
105. Phan TG, Wong RC, Crotty K, Adelstein S. Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin. Australas J Dermatol 1999; 40: 153-7.
106. Magina S, Lisboa C, Goncalves E, Conceicao F, Leal V, Mesquita-Guimaraes J. A case of toxic epidermal necrolysis treated with intravenous immunoglobin. Br J Dermatol 2000; 142: 191-2.
107. Andresen M, Boghero Y, Molgo M, Dougnao A, Diaz O. Toxic epidermal necrolysis. Therapy in ICU with intravenous immunoglobulins in a case. Rev Med Chil 2000; 128: 1343-8.
108. Corne P, Dereure O, Guilhou JJ, Jonquet O. Toxic epidermal necrolysis treated with intravenous immunoglobulins. Rev Med Interne 2001; 22: 491-2.
109. Paquet P, Jacob E, Damas P, Pierard GE. Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins. Burns 2001; 27: 652-5.
110. Stella M, Cassano P, Bollero D, Clemente A, Giorio G. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology 2001; 203: 45-9.
111. Prins C, Kerdel FA, Padilla RS et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003; 139: 26-32.
112. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using Scorten: The University of Miami Experience. Arch Dermatol 2003; 139: 39-43.
113. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003; 139: 33-6.
114. Xu C, Poirier B, Van Huyen JP et al. Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases. Am J Pathol 1998; 153: 1257-66.
115. Nakatani K, Takeshita S, Tsujimoto H, Sekine I. Intravenous immunoglobulin (IVIG) preparations induce apoptosis in TNF-α-stimulated endothelial cells via a mitochondria-dependent pathway. Clin Exp Immunol 2002; 127: 445-54.
116. Tsujimoto H, Takeshita S, Nakatani K, Kawamura Y, Tokutomi T, Sekine I. Intravenous immunoglobulin therapy induces neutrophil apoptosis in Kawasaki disease. Clin Immunol 2002; 103: 161-8.
117. Ekberg C, Nordstrom E, Skansen-Saphir U et al. Human polyspecific immunoglobulin for therapeutic use induces p21/WAF-1 and Bcl-2, which may be responsible for G1 arrest and long-term survival. Hum Immunol 2001; 62: 215-27.
118. Miller DJ, Rodriguez M. A monoclonal autoantibody that promotes central nervous system remyelination in a model of multiple sclerosis is a natural autoantibody encoded by germline immunoglobulin genes. J Immunol 1995; 154: 2460-9.
119. Warrington AE, Asakura K, Bieber AJ et al. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci USA 2000; 97: 6820-5.
120. Asakura K, Miller DJ, Pease LR, Rodriguez M. Targeting of IgMkappa antibodies to oligodendrocytes promotes CNS remyelination. J Neurosci 1998; 18: 7700-8.
121. Kuhlmann T, Wendling U, Nolte C et al. Differential regulation of myelin phagocytosis by macrophages/microglia, involvement of target myelin, Fc receptors and activation by intravenous immunoglobulins. J Neurosci Res 2002; 67: 185-90.
122. Stangel M, Compston A. Polyclonal immunoglobulins (IVIg) modulate nitric oxide production and microglial functions in vitro via Fc receptors. J Neuroimmunol 2001; 112: 63-71.
123. Achiron A, Gabbay U, Gilad R et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998; 50: 398-402.
124. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997; 349: 589-93.
125. Sorensen PS, Wanscher B, Jensen CV et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998; 50: 1273-81.
126. Noseworthy JH, O'Brien PC, Weinshenker BG, et al. IV immunoglobulin does not reverse established weakness in MS. Neurology 2000; 55: 1135-43.
127. Noseworthy JH, O'Brien PC, Petterson TM et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001; 56: 1514-22.
128. Stangel M, Boegner F, Klatt CH, Hofmeister C, Seyfert S. Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 68: 89-92.
129. Kazatchkine MD, Dietrich G, Hurez V et al. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v.lg). Immunol Rev 1994; 139: 79-107.
130. Rossi F, Kazatchkine MD. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol 1989; 143: 4104-9.
131. Rossi F, Sultan Y, Kazatchkine MD. Anti-idiotypes against autoantibodies and alloantibodies to VIII: C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin Exp Immunol 1988; 74: 311-16.
132. Dietrich G, Kazatchkine MD. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest 1990; 85: 620-5.
133. Van Doorn PA, Rossi F, Brand A, Van Lint M, Vermeulen M, Kazatchkine MD. On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1990; 29: 57-64.
134. Berchtold P, Dale GL, Tani P, Mcmillan R. Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin. Blood 1989; 74: 2414-17.
135. Hurez V, Kazatchkine MD, Vassilev T et al. Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease. Blood 1997; 90: 4004-13.
136. Saoudi A, Hurez V, De Kozak Y et al. Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int Immunol 1993; 5: 1559-67.
137. Jayne DR, Esnault VL, Lockwood CM. Anca anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. J Autoimmun 1993; 6: 207-19.
138. Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome. Ann Neurol 2002; 51: 673-80.
139. Dwyer DS, Bradley RJ, Urquhart CK, Kearney JF. Naturally occurring anti-idiotypic antibodies in myasthenia gravis patients. Nature 1983; 301: 611-14.
140. Rossi F, Jayne DR, Lockwood CM, Kazatchkine MD. Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol 1991; 83: 298-303.
141. Zouali M, Eyquem A. Expression of anti-idiotypic clones against auto-anti-DNA antibodies in normal individuals. Cell Immunol 1983; 76: 137-47.
142. Sultan Y, Rossi F, Kazatchkine MD. Recovery from anti-VIII: C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII: C autoantibodies. Proc Natl Acad Sci USA 1987; 84: 828-31.
143. Shoenfeld Y, Rauova L, Gilburd B et al. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 2002; 14: 1303-11.
144. Dietrich G, Algiman M, Sultan Y, Nydegger UE, Kazatchkine MD. Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg). Blood 1992; 79: 2946-51.
145. Dietrich G, Kaveri SV, Kazatchkine MD. A V region-connected autoreactive subfraction of normal human serum immunoglobulin G. Eur J Immunol 1992; 22: 1701-6.
146. Vassilev T, Gelin C, Kaveri SV, Zilber MT, Boumsell L, Kazatchkine MD. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol 1993; 92: 369-72.
147. Glotz D, Haymann JP, Sansonetti N et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (Mg). A potential tool for transplantation of immunized patients. Transplantation 1993; 56: 335-7.
148. Semple JW, Kim M, Lazarus AH, Freedman J. Gamma-globulins prepared from sera of multiparous women bind anti-HLA antibodies and inhibit an established in vivo human alloimmune response. Blood 2002; 100: 1055-9.
149. Varela F, Andersson A, Dietrich G et al. Population dynamics of natural antibodies in normal and autoimmune individuals. Proc Natl Acad Sci USA 1991; 88: 5917-21.
150. Dietrich G, Varela FJ, Hurez V, Bouanani M, Kazatchkine MD. Selection of the expressed B cell repertoire by infusion of normal immunoglobulin G in a patient with autoimmune thyroiditis. Eur J Immunol 1993; 23: 2945-50.
151. Stohl W. Modulation of the immune response by immunoglobulin for intravenous use. I. Inhibition of pokeweed mitogen-induced B cell differentiation. Clin Exp Immunol 1985; 62: 200-7.
152. Klaesson S, Tammik L, Markling L, Lundkvist I, Ringden O. Inhibition of immunoglobulin production in vitro by IgG and F(ab′)2 fragments, but not by the Fc portion. Scand J Immunol 1996; 43: 574-82.
153. Zhuang Q, Mazer B. Inhibition of IgE production in vitro by intact and fragmented intravenous immunoglobulin. J Allergy Clin Immunol 2001; 108: 229-34.
154. Osei A, Uttenreuther-Fischer MM, Lerch H, Gaedicke G, Fischer P. Restricted VH3 gene usage in phage-displayed Fab that are selected by intravenous immunoglobulin. Arthritis Rheum 2000; 43: 2722-32.
155. Leucht S, Uttenreuther-Fischer MM, Gaedicke G, Fischer P. The B cell superantigen-like interaction of intravenous immunoglobin (IVIG) with Fab fragments of V(H) 3-23 and 3-30/3-30.5 germline gene origin cloned from a patient with Kawasaki disease is enhanced after IVIG therapy. Clin Immunol 2001; 99: 18-29.
156. De Grandmont MJ, Racine C, Roy A, Lemieux R, Neron S. Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG. Blood 2003; 101: 3065-73.
157. Sundblad A, Marcos M, Huetz F et al. Normal serum immunoglobulins influence the numbers of bone marrow pre-B and B cells. Eur J Immunol 1991; 21: 1155-61.
158. Sundblad A, Huetz F, Portnoi D, Coutinho A. Stimulation of B and T cells by in vivo high dose immunoglobulin administration in normal mice. J Autoimmun 1991; 4: 325-39.
159. Hurez V, Kaveri SV, Mouhoub A et al. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg). Ther Immunol 1994; 1: 269-77.
160. Kaveri S, Vassilev T, Hurez V et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CDS T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996; 97: 865-9.
161. Vassilev TL, Kazatchkine MD, Van Huyen JP et al. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood 1999; 93: 3624-31.
162. Mazer BD, Gelfand EW. An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma. J Allergy Clin Immunol 1991; 87: 976-83.
163. Salmun LM, Barlan I, Wolf HM et al. Effect of intravenous immunoglobulin on steroid consumption in patients with severe asthma: a double-blind, placebo-controlled, randomized trial. J Allergy Clin Immunol 1999; 103(5 Pt 1): 810-5.
164. Silverman ED, Laxer RM, Greenwald M et al. Intravenous gamma globulin therapy in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1990; 33: 1015-22.
165. Gedalia A, Correa H, Kaiser M, Sorensen R. Case report: steroid sparing effect of intravenous gamma globulin in a child with necrotizing vasculitis. Am J Med Sci 1995; 309: 226-8.
166. Van Doom PA, Brand A, Strengers PF, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 1990; 40: 209-12.
167. Herman KE, Black MM. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br J Dermatol 1999; 140: 865-74.
168. Sami N, Qureshi A, Ruocco E, Ahmed AR. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol 2002; 138: 1158-62.
169. Ahmed AR. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001; 45: 825-35.
170. Sami N, Qureshi A, Ahmed AR. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus. Eur J Dermatol 2002; 12: 174-8.
171. Spahn JD, Leung DY, Chan MT, Szefler SJ, Gelfand EW. Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin. J Allergy Clin Immunol 1999; 103(3 Pt 1): 421-6.